Gene-editing co CRISPR falls after unveiling $350 mln convertible debt deal

Crispr Therapeutics AG

10/03/2026 11:29

** US-listed shares of Swiss gene-editing co CRISPR Therapeutics CRSP.O down 5.6% to $55.51 before the bell as it looks to raise capital

** Biopharma firm offering privately $350 mln 5-yr convertible bonds

** It intends to use net offering proceeds for general corp purposes

** Co has $5.6 bln market cap based on ~96 mln shares outstanding

** US-listed shares closed up 4% at $58.78 on Mon. Shares up 12% YTD and up 29% over the past 12 months

** Of 29 analysts covering CRSP, 17 rate "strong buy" or "buy", 11 rate "hold", and 1 recommends "sell"; median PT $78, per LSEG

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))